Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

• Published in: Clinical cancer research 2009-04, Vol.15 (7), p.2531-2540
• Main Authors: VERDIJK, Pauline, AARNTZEN, Erik H. J. G, BLOKX, Willeke, VAN KRIEKEN, J. Han J. M, JOOSTEN, Irma, BOERMAN, Otto C, OYEN, Wim J. G, ADEMA, Gosse, PUNT, Cornelis J. A, FIGDOR, Carl G, DE VRIES, I. Jolanda M, JOOST LESTERHUIS, W, INGE BOULLART, A. C, KOK, Ellemieke, VAN ROSSUM, Michelle M, STRIJK, Simon, EIJCKELER, Femke, BONENKAMP, Johannes J, JACOBS, Joannes F. M
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; Biological and medical sciences; Cancer Vaccines - administration & dosage; Cancer Vaccines - pharmacokinetics; Cell Movement; dendritic cells; Dendritic Cells - immunology; Dendritic Cells - transplantation; Dermatology; Humans; immunotherapy; Injections; lymph nodes; Lymph Nodes - immunology; Lymphocyte Activation; Medical sciences; Melanoma - immunology; Melanoma - metabolism; Phagocytosis; Pharmacology. Drug treatments; Skin Neoplasms - immunology; Skin Neoplasms - metabolism; T-Lymphocytes - immunology; Tumors of the skin and soft tissue. Premalignant lesions
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-08-2729

Purpose: The success of immunotherapy with dendritic cells (DC) to treat cancer is dependent on effective migration to the lymph nodes and subsequent activation of antigen-specific T cells. In this study, we investigated the fate of DC after intradermal (i.d.) or intranodal (i.n.) administration and the consequences for the immune activating potential of DC vaccines in melanoma patients. Experimental Design: DC were i.d. or i.n. administered to 25 patients with metastatic melanoma scheduled for regional lymph node resection. To track DC in vivo with scintigraphic imaging and in lymph nodes by immunohistochemistry, cells were labeled with both [ 111 In]-indium and superparamagnetic iron oxide. Results: After i.d. injection, maximally 4% of the DC reached the draining lymph nodes. When correctly delivered, all DC were delivered to one or more lymph nodes after i.n. injection. Independent of the route of administration, large numbers of DC remained at the injection site, lost viability, and were cleared by infiltrating CD163+ macrophages within 48 hours. Interestingly, 87 ± 10% of the surviving DC preferentially migrated into the T-cell areas, where they induced antigen-specific T-cell responses. Even though more DC reached the T-cell areas, i.n. injection of DC induced similar antigen-specific immune responses as i.d. injection. Immune responses were already induced with